Form 4: Solid Biosciences Executive Paul Herzich Reports Stock Transactions

Paul Herzich, Chief Technology Officer of Solid Biosciences Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On February 13, 2025, Paul Herzich, Chief Technology Officer of Solid Biosciences Inc., vested 7,187 restricted stock units (RSUs) which converted into common stock.
• Following the vesting, Mr. Herzich sold 2,688 shares of common stock on February 14, 2025, at a price of $3.96 per share to cover withholding taxes.
• These transactions were executed under a pre-arranged plan adopted on August 16, 2024, to manage tax obligations related to RSU vesting.
• After these transactions, Mr. Herzich directly owns 18,388 shares of Solid Biosciences Inc. common stock and 21,563 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine stock transactions related to RSU vesting and tax obligations. There is no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into the transactions of those with access to inside information.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to executive compensation and tax obligations.

Key Dates